Trade Citius Pharmaceuticals, Inc. - CTXR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading сonditions
| Spread | 0.0051 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Citius Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 0.792 |
| Open* | 0.7688 |
| 1-Year Change* | -53.26% |
| Day's Range* | 0.7277 - 0.7876 |
| 52 wk Range | 0.60-1.71 |
| Average Volume (10 days) | 678.56K |
| Average Volume (3 months) | 11.89M |
| Market Cap | 119.23M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 158.97M |
| Revenue | N/A |
| EPS | -0.22 |
| Dividend (Yield %) | N/A |
| Beta | 1.44 |
| Next Earnings Date | Feb 8, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 19, 2024 | 0.7452 | -0.0624 | -7.73% | 0.8076 | 0.8076 | 0.7181 |
| Apr 18, 2024 | 0.7920 | -0.2256 | -22.17% | 1.0176 | 1.0176 | 0.7516 |
| Apr 17, 2024 | 0.8138 | 0.0712 | 9.59% | 0.7426 | 0.8327 | 0.7288 |
| Apr 16, 2024 | 0.7440 | -0.0036 | -0.48% | 0.7476 | 0.7602 | 0.7276 |
| Apr 15, 2024 | 0.7558 | -0.0218 | -2.80% | 0.7776 | 0.7797 | 0.7476 |
| Apr 12, 2024 | 0.7839 | -0.0137 | -1.72% | 0.7976 | 0.8177 | 0.7676 |
| Apr 11, 2024 | 0.8275 | -0.0226 | -2.66% | 0.8501 | 0.8626 | 0.7476 |
| Apr 10, 2024 | 0.8475 | -0.0001 | -0.01% | 0.8476 | 0.8676 | 0.8279 |
| Apr 9, 2024 | 0.8877 | -0.0599 | -6.32% | 0.9476 | 0.9586 | 0.8581 |
| Apr 8, 2024 | 0.9580 | -0.0096 | -0.99% | 0.9676 | 0.9876 | 0.9476 |
| Apr 5, 2024 | 0.9976 | 0.0800 | 8.72% | 0.9176 | 1.0076 | 0.8977 |
| Apr 4, 2024 | 0.9391 | -0.0185 | -1.93% | 0.9576 | 0.9626 | 0.9110 |
| Apr 3, 2024 | 0.9577 | -0.0069 | -0.72% | 0.9646 | 0.9976 | 0.9414 |
| Apr 2, 2024 | 0.9709 | -0.0767 | -7.32% | 1.0476 | 1.0576 | 0.9276 |
| Apr 1, 2024 | 1.0076 | 0.1002 | 11.04% | 0.9074 | 1.0576 | 0.8978 |
| Mar 28, 2024 | 0.8880 | 0.0853 | 10.63% | 0.8027 | 0.9276 | 0.8026 |
| Mar 27, 2024 | 0.8144 | 0.0278 | 3.53% | 0.7866 | 0.8269 | 0.7726 |
| Mar 26, 2024 | 0.8011 | -0.0105 | -1.29% | 0.8116 | 0.8117 | 0.7676 |
| Mar 25, 2024 | 0.8030 | 0.0256 | 3.29% | 0.7774 | 0.8361 | 0.7676 |
| Mar 22, 2024 | 0.7843 | 0.0388 | 5.20% | 0.7455 | 0.7846 | 0.7186 |
Citius Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Friday, May 10, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q2 2024 Citius Pharmaceuticals Inc Earnings Release Q2 2024 Citius Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Monday, August 12, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2024 Citius Pharmaceuticals Inc Earnings Release Q3 2024 Citius Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 33.3161 | 23.3653 | 17.7107 | 15.5984 | 13.3391 |
| Selling/General/Admin. Expenses, Total | 15.6606 | 11.2914 | 8.89788 | 7.00146 | 7.22622 |
| Research & Development | 17.6555 | 12.2405 | 8.81281 | 8.5969 | 6.56293 |
| Operating Income | -33.3161 | -23.3653 | -17.7107 | -15.5984 | -13.3391 |
| Interest Income (Expense), Net Non-Operating | 0.2514 | 0.25099 | 0.0524 | 0.03622 | -0.01584 |
| Net Income Before Taxes | -33.0647 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Net Income After Taxes | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Net Income Before Extra. Items | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Net Income | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Income Available to Common Excl. Extra. Items | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Income Available to Common Incl. Extra. Items | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Diluted Net Income | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Diluted Weighted Average Shares | 146.082 | 108.599 | 39.1652 | 20.1618 | 10.7319 |
| Diluted EPS Excluding Extraordinary Items | -0.23029 | -0.22565 | -0.44805 | -0.77186 | -1.16817 |
| Diluted Normalized EPS | -0.23029 | -0.22718 | -0.44805 | -0.77186 | -1.2101 |
| Unusual Expense (Income) | 0 | -0.16656 | 0 | -0.45 | |
| Other, Net | 0 | 0.05992 | 0.11021 | 0 | 0.81834 |
| Total Adjustments to Net Income | 0 | -1.45088 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 8.67211 | 10.6853 | 3.66419 | 7.54957 | 8.91665 |
| Selling/General/Admin. Expenses, Total | 4.90744 | 5.95845 | 3.80437 | 3.69234 | 4.02846 |
| Research & Development | 3.76468 | 4.72686 | 3.44552 | 3.85723 | 4.88819 |
| Operating Income | -8.67211 | -10.6853 | -3.66419 | -7.54957 | -8.91665 |
| Interest Income (Expense), Net Non-Operating | 0.33678 | 0.30328 | 0.21455 | 0.13483 | 0.05302 |
| Other, Net | 0 | 0 | |||
| Net Income Before Taxes | -8.33533 | -10.382 | -3.44965 | -7.41474 | -8.86363 |
| Net Income After Taxes | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Net Income Before Extra. Items | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Net Income | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Income Available to Common Excl. Extra. Items | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Income Available to Common Incl. Extra. Items | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Diluted Net Income | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Diluted Weighted Average Shares | 153.775 | 146.252 | 146.211 | 146.146 | 146.13 |
| Diluted EPS Excluding Extraordinary Items | -0.05514 | -0.07197 | -0.02458 | -0.05468 | -0.06066 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.05514 | -0.07197 | -0.04052 | -0.05468 | -0.06066 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Unusual Expense (Income) | 0 | 0 | -3.58569 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 44.5643 | 72.8143 | 13.982 | 7.94192 | 10.0601 |
| Cash and Short Term Investments | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Cash & Equivalents | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Prepaid Expenses | 2.85258 | 2.7414 | 0.12224 | 0.04811 | 0.05773 |
| Total Assets | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Property/Plant/Equipment, Total - Net | 0.65017 | 0.82985 | 0.98778 | 0.00059 | 0.00148 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 1.5868 |
| Intangibles, Net | 59.4 | 59.4 | 19.4 | 19.4 | 19.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.05709 | 0.05709 | 0.00217 |
| Total Current Liabilities | 4.53001 | 3.98229 | 4.09713 | 4.60772 | 3.18484 |
| Accounts Payable | 1.16538 | 1.2771 | 1.85624 | 2.71354 | 1.57344 |
| Accrued Expenses | 3.36463 | 2.7052 | 2.06793 | 1.72121 | 1.43843 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.17297 | 0.17297 | 0.17297 |
| Other Current Liabilities, Total | 0 | ||||
| Total Liabilities | 11.1734 | 10.2467 | 10.103 | 9.59352 | 3.18484 |
| Total Long Term Debt | 0 | 0 | 0.16458 | 0 | 0 |
| Total Equity | 102.826 | 132.182 | 33.6707 | 27.1529 | 27.8657 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.14621 | 0.14598 | 0.05558 | 0.02893 | 0.0162 |
| Additional Paid-In Capital | 232.368 | 228.084 | 104.209 | 80.1697 | 68.1073 |
| Retained Earnings (Accumulated Deficit) | -129.688 | -96.0478 | -70.5939 | -53.0458 | -40.2578 |
| Total Liabilities & Shareholders’ Equity | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Total Common Shares Outstanding | 146.211 | 145.979 | 55.577 | 28.9305 | 16.1988 |
| Total Receivables, Net | 0.81834 | ||||
| Long Term Debt | 0 | 0.16458 | 0 | ||
| Deferred Income Tax | 5.5618 | 4.9858 | 4.9858 | 4.9858 | |
| Other Liabilities, Total | 0.48125 | 0.67823 | 0.85547 | ||
| Minority Interest | 0.60038 | 0.60038 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 41.1142 | 34.9011 | 42.3174 | 44.5643 | 50.8345 |
| Cash and Short Term Investments | 33.2818 | 29.0655 | 36.8872 | 41.7117 | 48.0442 |
| Cash & Equivalents | 33.2818 | 29.0655 | 36.8872 | 41.7117 | 48.0442 |
| Prepaid Expenses | 7.83232 | 5.8356 | 5.43013 | 2.85258 | 2.79032 |
| Total Assets | 110.405 | 104.241 | 111.705 | 113.999 | 120.316 |
| Property/Plant/Equipment, Total - Net | 0.50583 | 0.55484 | 0.60299 | 0.65017 | 0.69642 |
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 9.3468 |
| Intangibles, Net | 59.4 | 59.4 | 59.4 | 59.4 | 59.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.03806 | 0.03806 | 0.03806 |
| Total Current Liabilities | 5.79086 | 6.20968 | 4.53717 | 4.53001 | 4.46112 |
| Accounts Payable | 3.07967 | 2.72559 | 1.53758 | 1.16538 | 1.69052 |
| Accrued Expenses | 2.71119 | 3.48408 | 2.99959 | 3.36463 | 2.7706 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 12.7051 | 13.0347 | 11.2719 | 11.1734 | 10.5802 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Deferred Income Tax | 5.9938 | 5.8498 | 5.7058 | 5.5618 | 4.9858 |
| Minority Interest | 0.60038 | 0.60038 | 0.60038 | 0.60038 | 0.60038 |
| Other Liabilities, Total | 0.32001 | 0.37483 | 0.42857 | 0.48125 | 0.53288 |
| Total Equity | 97.6998 | 91.2061 | 100.433 | 102.826 | 109.736 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.15886 | 0.14636 | 0.14621 | 0.14621 | 0.14613 |
| Additional Paid-In Capital | 249.828 | 234.868 | 233.569 | 232.368 | 231.287 |
| Retained Earnings (Accumulated Deficit) | -152.287 | -143.808 | -133.282 | -129.688 | -121.698 |
| Total Liabilities & Shareholders’ Equity | 110.405 | 104.241 | 111.705 | 113.999 | 120.316 |
| Total Common Shares Outstanding | 158.858 | 146.358 | 146.211 | 146.211 | 146.13 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Cash From Operating Activities | -28.3613 | -24.2504 | -16.9307 | -12.4377 | -11.3181 |
| Cash From Operating Activities | 0.00292 | 0.00149 | 0.00084 | 0.00089 | 0.00175 |
| Non-Cash Items | 4.46091 | 1.5198 | 1.48355 | 0.92758 | 0.7069 |
| Cash Taxes Paid | |||||
| Cash Interest Paid | 0 | 0.00019 | |||
| Changes in Working Capital | 0.23956 | -2.71727 | -0.86697 | 2.19592 | 0.50985 |
| Cash From Investing Activities | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Other Investing Cash Flow Items, Total | 0 | ||||
| Cash From Financing Activities | 0 | 120.471 | 22.8984 | 11.1475 | 17.298 |
| Financing Cash Flow Items | 0 | 18.4504 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | -0.17297 | 0.16458 | 0 | 0 |
| Net Change in Cash | -28.3613 | 56.2132 | 5.96594 | -1.2902 | 5.9799 |
| Capital Expenditures | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 0 | 102.193 | 22.7339 | 11.1475 | 17.298 |
| Deferred Taxes | 0.576 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.1197 | -3.59365 | -33.6407 | -25.6499 | -16.7863 |
| Cash From Operating Activities | -12.6774 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Operating Activities | 0.00146 | 0.00073 | 0.00292 | 0.00219 | 0.00146 |
| Non-Cash Items | 2.56255 | 1.24754 | 4.46091 | 3.3344 | 2.28611 |
| Changes in Working Capital | -1.40977 | -2.62306 | 0.23956 | 0.28456 | 0.18199 |
| Cash From Financing Activities | 0.03127 | 0 | 0 | 0 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.03127 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
| Net Change in Cash | -12.6462 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Investing Activities | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | |||
| Deferred Taxes | 0.288 | 0.144 | 0.576 | ||
| Other Investing Cash Flow Items, Total | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Citius Pharmaceuticals, Inc. Company profile
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution for treating patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering with hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, a engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.| Industry: | Biotechnology & Medical Research (NEC) |
11 Commerce Dr Fl 1
CRANFORD
NEW JERSEY 07016-3501
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com